Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antibody-Drug Conjugate Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment Advanced Refractory Solid Tumors With HER-2 Positive(PRaG3.0)

NCT05115500 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT05115500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05115500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antibody-Drug Conjugate Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment Advanced Refractory Solid Tumors With HER-2 Positive(PRaG3.0)
Lead sponsor
Second Affiliated Hospital of Soochow University
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2021
Completion date
April 30, 2025
Enrollment
55 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, solid tumor